What is Losarmepha?
Losarmepha is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure may reduce the risk of strokes and heart attacks.
Losarmepha is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body that causes blood vessels to tighten. As a result, Losarmepha relaxes the blood vessels. A lower blood pressure will increase the supply of the blood and oxygen to the heart.
Losarmepha is also used to decrease the risk of stroke in patients with high blood pressure and enlargement of the heart. It is also used to treat kidney problems in patients with type 2 diabetes and a history of hypertension.
Losarmepha is available only with your doctor's prescription.
Losarmepha indications
Losarmepha is used to treat high blood pressure (hypertension). High blood pressure adds to the work load of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.
Losarmepha works by blocking the action of a substance in the body that causes blood vessels to tighten. As a result, Losarmepha relaxes blood vessels. This lowers blood pressure.
Losarmepha is also used to decrease the risk of stroke in patients with high blood pressure and a condition called left ventricular hypertrophy (LVH). LVH is an enlargement of the left pumping chamber of the heart and can cause problems with the way the heart pumps blood.
Losarmepha is also used to treat a condition called diabetic nephropathy. Diabetic nephropathy is a complication of type 2 diabetes which causes the kidneys to not work properly.
How should I use Losarmepha?
Use Losarmepha as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Losarmepha. Talk to your pharmacist if you have questions about this information.
- Take Losarmepha by mouth with or without food.
- If you cannot swallow tablets, ask your doctor or pharmacist about preparing a suspension of Losarmepha.
- Take Losarmepha on a regular schedule to get the most benefit from it. Taking Losarmepha at the same time each day will help you remember to take it.
- Continue to take Losarmepha even if you feel well. Do not miss any doses.
- If you miss a dose of Losarmepha, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Losarmepha.
Uses of Losarmepha in details
Use: Labeled Indications
Hypertension: Management of hypertension in adults and children ≥6 years of age
Proteinuric chronic kidney disease, diabetic: Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension
Off Label Uses
Heart failure with reduced ejection fraction
Data from a randomized, double-blind, dose comparison study in patients with New York Heart Association (NYHA) class II to IV heart failure support the use of Losarmepha at higher doses to reduce the rate of death or admission for heart failure in patients with heart failure.
Proteinuric chronic kidney disease, nondiabetic
Based on the 2012 Kidney Disease Improving Global Outcomes guidelines, the use of an ACE inhibitor or an ARB is recommended in patients with proteinuric CKD to prevent progression of CKD.
ST-elevation myocardial infarction
Based on the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infraction, an ARB is recommended and effective in patients who have indications for but are intolerant of ACE inhibitors.
Losarmepha description
Losarmepha POTASSIUM (Losarmepha), the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT1) antagonist. Losarmepha POTASSIUM (Losarmepha) also provides a reduction in the combined risk of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy and renal protection for type 2 diabetic patients with proteinuria.
Losarmepha potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol monopotassium salt.
Its empirical formula is C22H22ClKN6O.
Losarmepha potassium is a white to off-white free-flowing crystalline powder with a molecular weight of 461.01. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents, such as acetonitrile and methyl ethyl ketone.
Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of Losarmepha.
Losarmepha dosage
Hypertension: The usual starting and maintenance dose is 50 mg once daily for most patients. The maximal antihypertensive effect is attained 3-6 weeks after initiation of therapy. Some patients may receive an additional benefit by increasing the dose to 100 mg once daily.
For patients with intravascular volume-depletion (e.g., those treated with high-dose diuretics), a starting dose of 25 mg once daily should be considered.
No initial dosage adjustment is necessary for elderly patients or for patients with renal impairment, including patients on dialysis. A lower dose should be considered for patients with a history of hepatic impairment.
Reduction in the Risk of Cardiovascular Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy: The usual starting dose is 50 mg of Losarmepha POTASSIUM (Losarmepha) once daily. A low dose of hydrochlorothiazide should be added and/or the dose of Losarmepha POTASSIUM (Losarmepha) should be increased to 100 mg once daily based on blood pressure response.
Renal Protection in Type 2 Diabetic Patients with Proteinuria: The usual starting dose is 50 mg once daily. The dose may be increased to 100 mg once daily based on blood pressure response. Losarmepha POTASSIUM (Losarmepha) may be administered with other antihypertensive agents (e.g., diuretics, calcium channel blockers, alpha- or beta-blockers, and centrally acting agents) as well as with insulin and other commonly used hypoglycemic agents (e.g., sulfonylureas, glitazones and glucosidase inhibitors).
Administration: Losarmepha POTASSIUM (Losarmepha) may be administered with or without food.
Losarmepha POTASSIUM (Losarmepha) may be administered with other antihypertensive agents.
Losarmepha interactions
See also:
What other drugs will affect Losarmepha?
Concomitant use of Losarmepha with fenofibrate is beneficial in the treatment of patients with gout and hypertriglyceridemia.
Losarmepha shows no effect on the pharmacokinetics of warfarin and digoxin.
Administration of Losarmepha with fluconazole, phenytoin and grapefruit juice inhibits the metabolism of Losarmepha to its active metabolite. Although not yet established, the possibility of decreased therapeutic effect of Losarmepha may be considered.
Rifampicin was found to induce the metabolism of Losarmepha to its active metabolite, E3174 thereby, reducing levels of both Losarmepha and E3174 in the circulation.
Losarmepha does not affect the pharmacokinetic properties of phenytoin and orlistat.
Administration of Losarmepha with spironolactone and other potassium-sparing diuretics may lead to the occurrence of hyperkalemia. Physicians are advised to monitor patient's serum potassium level.
The use of Losarmepha with ACE inhibitors and β-blockers potentiates the antihypertensive effects of Losarmepha.
There have been reports of lithium intoxication when Losarmepha was given to patients treated with lithium.
Losarmepha side effects
See also:
What are the possible side effects of Losarmepha?
Losarmepha POTASSIUM (Losarmepha) has been found to be generally well tolerated in controlled clinical trials for hypertension; side effects have usually been mild and transient in nature and have not required discontinuation of therapy. The overall incidence of side effects reported with Losarmepha POTASSIUM (Losarmepha) was comparable to placebo.
In controlled clinical trials for essential hypertension, dizziness was the only side effect reported as drug related that occurred with an incidence greater than placebo in one percent or more of patients treated with Losarmepha POTASSIUM (Losarmepha). In addition, dose-related orthostatic effects were seen in less than one percent of patients. Rarely, rash was reported, although the incidence in controlled clinical trials was less than placebo.
In these double-blind controlled clinical trials for essential hypertension, the following adverse experiences reported with Losarmepha POTASSIUM (Losarmepha) occurred in ≥1 percent of patients, regardless of drug relationship:
Losarmepha POTASSIUM (Losarmepha) was generally well tolerated in a controlled clinical trial in hypertensive patients with left ventricular hypertrophy. The most common drug-related side effects were dizziness, asthenia/fatigue, and vertigo.
In the LIFE study, among patients without diabetes at baseline, there was a lower incidence of new onset diabetes mellitus with Losarmepha POTASSIUM (Losarmepha) as compared to atenolol (242 patients versus 320 patients, respectively, p<0.001). Because there was no placebo group included in the study, it is not known if this represents a beneficial effect of Losarmepha POTASSIUM (Losarmepha) or an adverse effect of atenolol.
Losarmepha POTASSIUM (Losarmepha) was generally well tolerated in a controlled clinical trial in type 2 diabetic patients with proteinuria. The most common drug-related side effects were asthenia/fatigue, dizziness, hypotension and hyperkalemia.
The following additional adverse reactions have been reported in post-marketing experience: Hypersensitivity: Anaphylactic reactions, angioedema including swelling of the larynx and glottis causing airway obstruction and/or swelling of the face, lips, pharynx and/or tongue has been reported rarely in patients treated with Losarmepha; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Vasculitis, including Henoch-Schoenlein purpura, has been reported rarely.
Gastrointestinal: Hepatitis (reported rarely), liver function abnormalities, vomiting.
General Disorders and Administration Site Conditions: Malaise.
Hematologic: Anemia, thrombocytopenia (reported rarely).
Musculoskeletal: Myalgia, arthralgia.
Nervous System/Psychiatric: Migraine, dysgeusia.
Reproductive System and Breast Disorders: Erectile dysfunction/impotence.
Respiratory: Cough.
Skin: Urticaria, pruritus, erythroderma, photosensitivity.
Laboratory Test Findings: In controlled clinical trials for essential hypertension, clinically important changes in standard laboratory parameters were rarely associated with administration of Losarmepha POTASSIUM (Losarmepha). Hyperkalemia (serum potassium >5.5 mEq/L) occurred in 1.5% of patients in the hypertension clinical trials. In a clinical study conducted in type 2 diabetic patients with proteinuria, 9.9% of patients treated with Losarmepha POTASSIUM (Losarmepha) and 3.4% of patients treated with placebo developed hyperkalemia. Elevations of ALT occurred rarely and usually resolved upon discontinuation of therapy.
Losarmepha contraindications
See also:
What is the most important information I should know about Losarmepha?
Do not use if you are pregnant. Stop using and tell your doctor right away if you become pregnant. Losarmepha can cause injury or death to the unborn baby if you take the medicine during your second or third trimester. Use effective birth control.
You should not use this medication if you are allergic to Losarmepha.
Before you use Losarmepha, tell your doctor about all your other medical conditions and allergies. Also make sure your doctor knows if you are pregnant or breast-feeding. In some cases, you may not be able to use Losarmepha, or you may need a dose adjustment or special precautions.
Certain other drugs may interact with Losarmepha or should not be used at the same time. Tell each of your healthcare providers about all medicines you use now, and any medicine you start or stop using.
Call your doctor if you have ongoing vomiting or diarrhea, or if you are sweating more than usual. You can easily become dehydrated while taking this medicine, which can lead to severely low blood pressure or a serious electrolyte imbalance.
In rare cases, Losarmepha can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. Call your doctor right away if you have unexplained muscle pain, tenderness, or weakness especially if you also have fever, unusual tiredness, and dark colored urine.
Active ingredient matches for Losarmepha:
Losartan in Egypt.
List of Losarmepha substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Losarmax (South Korea) | |
| LOSARPEN | |
| LOSARPEN TABLET 1 strip / 10 tablets each (Morepen Laboratories Ltd) | $ 0.23 |
| Losarpex (Bangladesh) | |
| Losarquilab (Peru) | |
| Losarstad (Denmark, Sweden) | |
| Losart (Bangladesh, Oman, Taiwan) | |
| Losart 50 mg x 100's (Concept) | |
| Losart 50 mg (Concept) | |
| Losart film-coated tab 50 mg 100's (Concept) | |
| Losarta (Israel) | |
| Losarta 12.5 (Israel) | |
| Losarta 50 (Israel) | |
| Losartam (South Korea) | |
| Losartan (Aruba, Australia, Bahamas, Bahrain, Barbados, Belgium, Brazil, Bulgaria, Canada, Cayman Islands, Chile, China, Costa Rica, Croatia (Hrvatska), El Salvador, Estonia, Finland, France, Georgia, Guatemala, Honduras, Hong Kong, Hungary, Indonesia, Ireland, Jamaica, Latvia, Lithuania, Malaysia, Malta, Mexico, Netherlands, New Zealand, Nicaragua, Norway, Panama, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Trinidad & Tobago, Tunisia, Turkey, United Kingdom, United States, Venezuela, Vietnam) | |
| Tablet, Film-Coated; Oral; Losartan Potassium 50 mg (Esp pharma) | |
| Tablet, Film-Coated; Oral; Losartan Potassium 100 mg (Esp pharma) | |
| Tablet, Film-Coated; Oral; Losartan Potassium 12.5 mg (Esp pharma) | |
| Tablet, Film-Coated; Oral; Losartan Potassium 25 mg (Esp pharma) | |
| Tablet, Film-Coated; Oral; Losartan Potassium 75 mg (Esp pharma) | |
| Tablet; Oral; Losartan Potassium 50 mg (Esp pharma) | |
| Tablet; Oral; Losartan Potassium 100 mg (Esp pharma) | |
| Tablet; Oral; Losartan Potassium 25 mg (Esp pharma) | |
| Losartan Potassium 90 50 mg tablet Bottle (Esp pharma) | $ 211.78 |
| Losartan Potassium-HCTZ 30 50-12.5 mg tablet Bottle (Esp pharma) | $ 78.05 |
| Hyzaar 100-25 mg tablet (Esp pharma) | $ 3.91 |
| Hyzaar 100-12.5 mg tablet (Esp pharma) | $ 3.87 |
| Hyzaar 100-12.5 tablet (Esp pharma) | $ 3.61 |
| Hyzaar 100-25 tablet (Esp pharma) | $ 3.61 |
| Losartan Potassium-HCTZ 100-12.5 mg tablet (Esp pharma) | $ 3.54 |
| Losartan Potassium-HCTZ 100-25 mg tablet (Esp pharma) | $ 3.54 |
| Cozaar 100 mg tablet (Esp pharma) | $ 1.31 |
| Losartan potassium 100 mg tablet (Esp pharma) | $ 3.14 |
| Hyzaar 50-12.5 mg tablet (Esp pharma) | $ 2.97 |
| Hyzaar 50-12.5 tablet (Esp pharma) | $ 2.65 |
| Cozaar 50 mg tablet (Esp pharma) | $ 1.31 |
| Losartan potassium 50 mg tablet (Esp pharma) | $ 2.26 |
| Cozaar 25 mg tablet (Esp pharma) | $ 1.31 |
| Losartan potassium 25 mg tablet (Esp pharma) | $ 1.72 |
| Losartan tablet 25 mg (Esp pharma) | |
| Losartan tablet 50 mg (Esp pharma) | |
| Losartan tablet 100 mg (Esp pharma) | |
| Losartan tablet, film coated 50 mg/1 (Esp pharma) | |
| Losartan tablet, film coated 100 mg/1 (Esp pharma) | |
| Losartan tablet, film coated 25 mg/1 (Esp pharma) | |
See 2038 substitutes for Losarmepha | |
References
- DailyMed. "LOSARTAN POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "losartan". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "losartan". http://www.drugbank.ca/drugs/DB00678 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Losarmepha are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Losarmepha. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
